Asta Medica, Aktiengesellschaft

Aeterna Zentaris Gmbh

Zentaris Gmbh

Zentaris Ag

Werner Sarlikiotis

Helmut Hettche

Matthias Rischer

Horst Bauer

Michael Damm

Dieter Sauerbier

Peter Hilgard

Thomas Klenner

Jürgen Engel

Anne Haaije De Boer

Juergen Engel

Eckhard Milsmann

Jurgen Rawert

Frank Güthlein

Dominique Di Stefano

The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.

Pharmaceutical administration form for peptides, process for its preparation, and use

A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.

An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Injectable solution of an LHRH antagonist

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

Novel, advantageous dosage forms of thioctic acid and the enantiomers thereof together with thioctic acid salts are described. The pharmaceutical formulations according to the invention are used for the production of pharmaceutical dosage forms which release the active ingredient more rapidly and have greater bioavailability than previous forms.

Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability

The invention relates to pharmaceutical forms for oral administration in the form of tablets, film-coated tablets, pellets or granules comprising at least 88% of mesna, produced by granulation with up to 15% of water, based on the amount of solid employed, and also tablets, film-coated tablets, pellets or granules comprising at least 80% of mesna, produced by direct compression or compaction, without the use of organic solvents.

Pharmaceutical forms for the oral administration of mesna

A pharmaceutical formulation for administration by inhalation, a micronized active compound or micronized active compound mixture with a mean particle size of 0.1 &mgr;m to 10 &mgr;m being applied to a pharmaceutically acceptable excipient having a mean particle size of 200 &mgr;m to 1000 &mgr;m without the use of binders.

Particulate formulation for administration by inhalation

Dosage forms containing thioctic acid or solid salts of thioctic acid

The invention relates to a drug formulation in the form of tablets containing thioctic acid (.alpha.-lipoic acid) with an active ingredient content between 45% by weight and 99.9% by weight. The invention is characterized in that 20% to 100% of the active ingredient used has a particle size exceeding 100 .mu.m, particulary between 100 .mu.m and 710 .mu.m, preferably 30% to 80% a particle size between 200 .mu.m and 710 .mu.m.

Growing community of inventors

Frankfurt-am-Main, Germany

Werner Sarlikiotis